Understanding the Perspective of Youths on Undergoing Metabolic Monitoring While on Second-Generation Antipsychotics: Challenges, Insight, and Implications

被引:1
|
作者
Aouira, Nisreen [1 ,7 ]
Khan, Sohil [1 ,2 ,3 ,4 ]
Heussler, Helen [2 ,5 ]
Haywood, Alison [1 ,2 ]
Karaksha, Abdullah [1 ]
Bor, William [2 ,5 ,6 ]
机构
[1] Griffith Univ, Menzies Hlth Inst Queensland, Sch Pharm & Med Sci, Gold Coast, Australia
[2] Univ Queensland, Mater Res Inst, Brisbane, Australia
[3] Prasanna Inst Publ Hlth, Manipal, India
[4] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Manipal, India
[5] Childrens Hlth Queensland Hosp & Hlth Serv, Brisbane, Australia
[6] Queensland Hlth, Ctr Childrens Hlth Res, Child & Youth Mental Hlth Serv, Brisbane, Australia
[7] Griffith Univ, Menzies Hlth Inst Queensland, Sch Pharm & Med Sci, Gold Coast 4222, Australia
关键词
youths; perspective; antipsychotics; barriers; suggestions; health; PSYCHOTROPIC MEDICATION; PHYSICAL-ACTIVITY; EXPERIENCE; BARRIERS; DEPRESSION; ADOLESCENTS; CHILDREN; CARE; PARTICIPATION; PERCEPTIONS;
D O I
10.1089/cap.2023.0016
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: Prescription of second-generation antipsychotics (SGAs) in youths is rapidly increasing globally, despite the potential for significant adverse effects and long-term health consequences. A known adverse reaction resulting from SGAs is metabolic syndrome (MS). Youths exposed to antipsychotics are at higher risk than adults for adverse drug reactions, including adverse events such as MS (with weight gain as the most significant adverse outcome) and other long-term endocrinological abnormalities. This study aimed to explore the experiences of young patients on factors impacting barriers to metabolic monitoring of SGAs and the strategies to address those barriers thereby providing further guidance on policy and service delivery.Methods: Semi-structured interviews were conducted with patients (youths who were prescribed SGAs) who attended Child and Youth Mental Health Services. The interviews focused on barriers to monitoring and strategies to enhance rates of monitoring that could be customized across study sites.Results: Young patients revealed that none of them had any concerns or objections to receiving anthropometric metabolic measurements. However, they seemed concerned to undergo blood tests as part of the metabolic monitoring process. Specifically, youths cited their fear of the needles as barrier to undergo the required blood tests. Youths have also reported that their dislike to healthy foods and exercise being the most common challenge they face while trying to engage in a healthy lifestyle to manage the SGAs resulted weight gain.Conclusion: Prescribers are recommended to actively engage young patients about the expected SGAs-induced adverse effects, the importance of conducting metabolic monitoring, and how to prevent and minimize the expected adverse effects from the start of initiating SGAs. This could be a vital step toward a successful treatment as the insight of youths into the details of the chosen treatment can play a significant role into treatment adherence and recovery.
引用
收藏
页码:279 / 286
页数:8
相关论文
共 50 条
  • [21] Metabolic monitoring of second-generation antipsychotics: Evaluation of a pharmacist- and nurse-driven protocol
    Hibner, Taylor A.
    Wakefield, Andrew N.
    Eaves, Shannon M.
    Gonzalvo, Jasmine D.
    Macik, Monica R.
    Williams, Gabriela D.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (05) : S88 - S92
  • [22] Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists
    Sanyal, Swarnava
    Rowan, Paul J.
    Ochoa-Perez, Melissa
    Calarge, Chadi
    Aparasu, Rajender
    Abughosh, Susan
    Chen, Hua
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2024, 34 (08) : 359 - 365
  • [23] Metabolic monitoring for patients on second-generation antipsychotics using electronic notifications as a reminder system for providers
    Parker, Stephanie
    Henderson, Rachel
    Dutton, Traci
    Pate, R. Jill
    Bean, Jennifer R.
    PHARMACOTHERAPY, 2016, 36 (12): : E272 - E272
  • [24] Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics
    Weissman, Ellen M.
    Zhu, Carolyn W.
    Schooler, Nina R.
    Goetz, Raymond R.
    Essock, Susan A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (09) : 1323 - 1326
  • [25] Second-generation antipsychotics and the metabolic syndrome in drug-naive adolescents
    Sjo, C.
    Bilenberg, N.
    EUROPEAN PSYCHIATRY, 2016, 33 : S263 - S263
  • [26] Effect of second-generation antipsychotics on cognition: current issues and future challenges
    Hill, S. Kristian
    Bishop, Jeffrey R.
    Palumbo, Donna
    Sweeney, John A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (01) : 43 - 57
  • [27] Metabolic side effects in children and adolescents treated with second-generation antipsychotics
    Alvarez-Segura, M.
    Fraguas, D.
    Merchan, J.
    Leiva, M.
    Barajas, A.
    Arango, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S563 - S563
  • [28] Second-generation (atypical) antipsychotics and metabolic effects - A comprehensive literature review
    Newcomer, JW
    CNS DRUGS, 2005, 19 : 1 - 93
  • [29] Second-Generation (Atypical) Antipsychotics and Metabolic EffectsA Comprehensive Literature Review
    John W. Newcomer
    CNS Drugs, 2005, 19 (Suppl 1) : 1 - 93
  • [30] Second-generation antipsychotics in major depressive disorder: update and clinical perspective
    Chen, Jun
    Gao, Keming
    Kemp, David E.
    CURRENT OPINION IN PSYCHIATRY, 2011, 24 (01) : 10 - 17